Hims & Hers Health beat Q4 earnings forecasts, though shares fell 2 per cent in aftermarket trading after the telehealth firm issued full-year guidance largely in line and a softer first quarter.
The company reported Q4 earnings per share of US$0.08, ahead of analyst expectations of $0.05. Revenue rose to US$617.8m, compared with consensus forecasts of $618.7m.
For full-year 2026, the firm forecast revenue of US$2.7bn to US$2.9bn, compared with consensus estimates of $2.75bn. It also projected adjusted EBITDA, a measure of operating profit, of US$300m to $375m.
However, first-quarter 2026 revenue guidance of US$600m to US$625m came in below consensus expectations of US$653.9m. Adjusted EBITDA for the quarter is forecast at US$35m to US$55m.
The results come amid pressure on the stock linked to regulatory scrutiny and competitive tensions in the weight-loss market.
Following a government ban on selling copycat drugs in bulk, the company rolled out more personalised versions of the active ingredient used in Novo Nordisk’s Wegovy, a prescription weight-loss injection.
Hims & Hers later withdrew its obesity pill earlier this month under scrutiny from the US Food and Drug Administration and faces lawsuits filed by Novo Nordisk.
Short interest in the company climbed to its highest level in at least a year in January. Shares have fallen more than 53 per cent so far in 2026 and are down over 69 per cent in the past year.
In November, the company said third-quarter subscribers rose 21 per cent year on year to 2.47 million, lifting quarterly revenue to US$600m and increasing monthly online revenue per average subscriber by 19 per cent to US$80.
